drugset / Trial / NCT06244485

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

NCT06244485

Phase 1 Recruiting 210 enrolled Daiichi Sankyo
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.

Timeline

Start
2024-02-16
Primary completion
2028-11-01
Completion
2028-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Datopotamab deruxtecan Monoclonal antibody Intravenous
Subject T-DXd Unknown Intravenous
Subject Valemetostat Small molecule Oral

Indications

No indication recorded.